UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 316

Sortiert nach

Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Schizophrenia research, 2018-05, Vol.195, p.275-282

2018

Volltextzugriff (PDF)

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline

Schizophrenia research, 2006-09, Vol.86 (1), p.15-22

2006

Volltextzugriff (PDF)

Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy

The American journal of psychiatry, 2011-07, Vol.168 (7), p.702-708

2011

Volltextzugriff (PDF)

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

The American journal of psychiatry, 2011-09, Vol.168 (9), p.947-956

2011

Volltextzugriff (PDF)

Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

The American journal of psychiatry, 2007-07, Vol.164 (7), p.1050-1060

2007

Volltextzugriff (PDF)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

BMC psychiatry, 2022-08, Vol.22 (1), p.1-574, Article 574

2022

Volltextzugriff (PDF)

Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia

American journal of human genetics, 2012-08, Vol.91 (2), p.303-312

2012

Volltextzugriff (PDF)

Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

The American journal of psychiatry, 2007-07, Vol.164 (7), p.1061-1071

2007

Volltextzugriff (PDF)

How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care

The journal of clinical psychiatry, 2020-11, Vol.81 (6)

McEvoy, Joseph P

2020

Volltextzugriff (PDF)

Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2011-02, Vol.36 (3), p.616-626

2011

Volltextzugriff (PDF)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

BMC psychiatry, 2021-03, Vol.21 (1), p.164-8, Article 164

2021

Volltextzugriff (PDF)

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

European journal of human genetics : EJHG, 2009-07, Vol.17 (7), p.946-957

2009

Volltextzugriff (PDF)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

CNS spectrums, 2014-08, Vol.19 (4), p.330-339

2014

Volltextzugriff (PDF)

Longitudinal study of inflammatory markers and psychopathology in schizophrenia

Schizophrenia research, 2020-10, Vol.224, p.58-66

2020

Volltextzugriff (PDF)

Use of Clozapine in Schizophrenia

JAMA psychiatry (Chicago, Ill.), 2016-10, Vol.73 (10), p.1097

McEvoy, Joseph P

2016

Volltextzugriff (PDF)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

CNS drugs, 2021-11, Vol.35 (11), p.1189-1205

2021

Volltextzugriff (PDF)

Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial

Schizophrenia research, 2005-12, Vol.80 (1), p.33-43

2005

Volltextzugriff (PDF)

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

Schizophrenia research, 2013-05, Vol.146 (1), p.190-195

2013

Volltextzugriff (PDF)

Meta-analysis of clozapine and insomnia in schizophrenia

Schizophrenia research, 2023-02, Vol.252, p.208-215

2023

Volltextzugriff (PDF)

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

The journal of clinical psychiatry, 2011-01, Vol.72 (1), p.75

2011

Volltextzugriff (PDF)

Improved insomnia is one pathway underlying the anti‐suicidal properties of clozapine

Suicide & life-threatening behavior, 2024-06

2024

Volltextzugriff (PDF)

Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Schizophrenia research, 2019-07, Vol.209, p.193-197

2019

Volltextzugriff (PDF)

Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

The journal of clinical psychiatry, 2020-01, Vol.81 (1)

2020

Volltextzugriff (PDF)

Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia

Schizophrenia research, 2022-12, Vol.250, p.134-136

2022

Volltextzugriff (PDF)

1 – 25 von 316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(296)
Mit Volltextzugriff
(269)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(222)
Life Sciences & Biomedicine
(219)
Humans
(216)
Psychiatry
(167)
Female
(146)
Male
(146)
Adult
(134)
Schizophrenia
(128)
Biological And Medical Sciences
(114)
Medical Sciences
(114)
Schizophrenia - Drug Therapy
(112)
Middle Aged
(97)
Psychology. Psychoanalysis. Psychiatry
(95)
Antipsychotic Agents - Therapeutic Use
(77)
Psychopathology. Psychiatry
(72)
Pharmacology. Drug Treatments
(68)
Schizophrenic Psychology
(60)
Double-Blind Method
(59)
Psychopharmacology
(59)
Adult And Adolescent Clinical Studies
(57)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline

Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy

A genome-wide investigation of SNPs and CNVs in schizophrenia

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia

Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care

Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

Longitudinal study of inflammatory markers and psychopathology in schizophrenia

Use of Clozapine in Schizophrenia

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

Meta-analysis of clozapine and insomnia in schizophrenia

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

Improved insomnia is one pathway underlying the anti‐suicidal properties of clozapine

Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia

Suchergebnisse filtern